In Vitro Diagnostics - Indonesia | Statista Market Forecast

The projected revenue for the In Vitro Diagnostics market market in Indonesia is estimated to reach US$382.60m in 2024.
It is anticipated that the revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 4.23%, leading to a market volume of US$470.60m by 2029.
When compared to other countries worldwide, the United States is expected to generate the highest revenue, amounting to US$30.10bn in 2024.
The demand for in vitro diagnostics in Indonesia is rapidly growing due to the increasing prevalence of chronic diseases.

Definition:
The market In Vitro Diagnostics (IVD) consists of medical instruments and accessories used to perform tests with the help of biological samples. In Vitro Diagnostics provide valuable information used for detection, prognosis, prevention, and therapeutic monitoring of diseases.

Additional information:
Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G). Revenues are allocated to the country where the money is spent.

Company examples: Roche Diagnostics, Abbott Laboratories, Danaher, Siemens Healthineers.
Further information on the key players can be found in the Market Shares boxes.

Molecular diagnosis
Immunoassays
Clinical chemistry
Microbiology
Hematology

Services (i.e., treatment expenses)
Imaging diagnostics

The In Vitro Diagnostics market in Indonesia is experiencing significant growth and development due to various factors.

Customer preferences: Customers in Indonesia are increasingly seeking access to advanced diagnostic tests and technologies. They are becoming more aware of the importance of early detection and diagnosis of diseases, leading to a growing demand for in vitro diagnostics. Additionally, the rising prevalence of chronic diseases in the country has further fueled the demand for diagnostic tests. Customers are also increasingly looking for convenience and accessibility in healthcare services, which has led to the adoption of point-of-care testing devices.

Trends in the market: One of the key trends in the In Vitro Diagnostics market in Indonesia is the increasing adoption of molecular diagnostics. This technology allows for the detection and analysis of genetic variations and biomarkers, enabling more accurate and personalized diagnosis and treatment. The demand for molecular diagnostics is being driven by the need for early detection of diseases such as cancer and infectious diseases. Another trend in the market is the growing use of rapid diagnostic tests. These tests provide quick results and are particularly useful in resource-limited settings where access to laboratory facilities may be limited. Rapid diagnostic tests are being widely used for the diagnosis of infectious diseases such as malaria, dengue, and HIV/AIDS.

Local special circumstances: Indonesia is a large and diverse country with a significant rural population. This poses challenges in terms of healthcare access and infrastructure. To overcome these challenges, there has been a focus on the development and implementation of innovative diagnostic solutions that are suitable for use in remote and rural areas. For example, there has been an increasing use of mobile health technologies and telemedicine to improve access to diagnostic services in underserved areas.

Underlying macroeconomic factors: The growing middle class in Indonesia, along with increasing healthcare expenditure, is driving the growth of the In Vitro Diagnostics market. As disposable incomes rise, more individuals are able to afford healthcare services, including diagnostic tests. Additionally, the government's focus on improving healthcare infrastructure and expanding access to healthcare services is also contributing to the growth of the market. In conclusion, the In Vitro Diagnostics market in Indonesia is experiencing significant growth and development due to increasing customer preferences for advanced diagnostic technologies, the adoption of molecular diagnostics and rapid diagnostic tests, local special circumstances such as the need for innovative solutions in rural areas, and underlying macroeconomic factors such as the growing middle class and government initiatives to improve healthcare infrastructure.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.